470 related articles for article (PubMed ID: 31160237)
41. A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial.
Hou J; Du X; Jin J; Cai Z; Chen F; Zhou DB; Yu L; Ke X; Li X; Wu D; Meng F; Ai H; Zhang J; Wortman-Vayn H; Chen N; Mei J; Wang J
J Hematol Oncol; 2013 Jun; 6():41. PubMed ID: 23782711
[TBL] [Abstract][Full Text] [Related]
42. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
[TBL] [Abstract][Full Text] [Related]
43. Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study.
Dimopoulos M; Wang M; Maisnar V; Minarik J; Bensinger W; Mateos MV; Obreja M; Blaedel J; Moreau P
J Hematol Oncol; 2018 Apr; 11(1):49. PubMed ID: 29615082
[TBL] [Abstract][Full Text] [Related]
44. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
Attal M; Richardson PG; Rajkumar SV; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Macé S; Corzo KP; Campana F; Le-Guennec S; Dubin F; Anderson KC;
Lancet; 2019 Dec; 394(10214):2096-2107. PubMed ID: 31735560
[TBL] [Abstract][Full Text] [Related]
45. Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma.
Ailawadhi S; Sexton R; Lentzsch S; Abidi MH; Voorhees PM; Cohen AD; Rohren EM; Heitner S; Kelly K; Mackler NJ; Baer DM; Hoering A; Durie B; Orlowski RZ
Clin Cancer Res; 2020 Aug; 26(15):3969-3978. PubMed ID: 32299820
[TBL] [Abstract][Full Text] [Related]
46. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
Chari A; Martinez-Lopez J; Mateos MV; Bladé J; Benboubker L; Oriol A; Arnulf B; Rodriguez-Otero P; Pineiro L; Jakubowiak A; de Boer C; Wang J; Clemens PL; Ukropec J; Schecter J; Lonial S; Moreau P
Blood; 2019 Aug; 134(5):421-431. PubMed ID: 31113777
[TBL] [Abstract][Full Text] [Related]
47. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
Hou J; Jin J; Xu Y; Wu D; Ke X; Zhou D; Lu J; Du X; Chen X; Li J; Liu J; Gupta N; Hanley MJ; Li H; Hua Z; Wang B; Zhang X; Wang H; van de Velde H; Richardson PG; Moreau P
J Hematol Oncol; 2017 Jul; 10(1):137. PubMed ID: 28683766
[TBL] [Abstract][Full Text] [Related]
48. Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program.
Du X; Jin J; Cai Z; Chen F; Zhou DB; Yu L; Ke X; Li X; Wu D; Meng F; DeMarco D; Zhang J; Mei J; Hou J
BMC Cancer; 2016 Jan; 16():46. PubMed ID: 26821931
[TBL] [Abstract][Full Text] [Related]
49. Modeling Covariate-Adjusted Survival for Economic Evaluations in Oncology.
Majer IM; Castaigne JG; Palmer S; DeCosta L; Campioni M
Pharmacoeconomics; 2019 May; 37(5):727-737. PubMed ID: 30610657
[TBL] [Abstract][Full Text] [Related]
50. Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma.
Dimopoulos MA; Orlowski RZ; Facon T; Sonneveld P; Anderson KC; Beksac M; Benboubker L; Roddie H; Potamianou A; Couturier C; Feng H; Ataman O; van de Velde H; Richardson PG
Haematologica; 2015 Jan; 100(1):100-6. PubMed ID: 25261096
[TBL] [Abstract][Full Text] [Related]
51. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
Sonneveld P; Goldschmidt H; Rosiñol L; Bladé J; Lahuerta JJ; Cavo M; Tacchetti P; Zamagni E; Attal M; Lokhorst HM; Desai A; Cakana A; Liu K; van de Velde H; Esseltine DL; Moreau P
J Clin Oncol; 2013 Sep; 31(26):3279-87. PubMed ID: 23897961
[TBL] [Abstract][Full Text] [Related]
52. Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma.
Fouquet G; Pegourie B; Macro M; Petillon MO; Karlin L; Caillot D; Roussel M; Arnulf B; Mathiot C; Marit G; Kolb B; Stoppa AM; Brechiniac S; Richez V; Rodon P; Banos A; Wetterwald M; Garderet L; Royer B; Hulin C; Benbouker L; Decaux O; Escoffre-Barbe M; Fermand JP; Attal M; Avet-Loiseau H; Moreau P; Facon T; Leleu X;
Ann Oncol; 2016 May; 27(5):902-7. PubMed ID: 26787238
[TBL] [Abstract][Full Text] [Related]
53. Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma.
Spicka I; Ocio EM; Oakervee HE; Greil R; Banh RH; Huang SY; D'Rozario JM; Dimopoulos MA; Martínez S; Extremera S; Kahatt C; Alfaro V; Carella AM; Meuleman N; Hájek R; Symeonidis A; Min CK; Cannell P; Ludwig H; Sonneveld P; Mateos MV
Ann Hematol; 2019 Sep; 98(9):2139-2150. PubMed ID: 31240472
[TBL] [Abstract][Full Text] [Related]
54. Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Iida S; Wakabayashi M; Tsukasaki K; Miyamoto K; Maruyama D; Yamamoto K; Takatsuka Y; Kusumoto S; Kuroda J; Ando K; Kikukawa Y; Masaki Y; Kobayashi M; Hanamura I; Asai H; Nagai H; Shimada K; Tsukamoto N; Inoue Y; Tobinai K
Cancer Sci; 2018 May; 109(5):1552-1561. PubMed ID: 29478257
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes.
Hari P; Mateos MV; Abonour R; Knop S; Bensinger W; Ludwig H; Song K; Hajek R; Moreau P; Siegel DS; Feng S; Obreja M; Aggarwal SK; Iskander K; Goldschmidt H
Leukemia; 2017 Dec; 31(12):2630-2641. PubMed ID: 28439109
[TBL] [Abstract][Full Text] [Related]
56. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial.
San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Schlossman RL; Hou J; Moreau P; Lonial S; Lee JH; Einsele H; Sopala M; Bengoudifa BR; Binlich F; Richardson PG
Lancet Haematol; 2016 Nov; 3(11):e506-e515. PubMed ID: 27751707
[TBL] [Abstract][Full Text] [Related]
57. Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials.
Martino EA; Palmieri S; Galli M; Derudas D; Mina R; Della Pepa R; Zambello R; Vigna E; Bruzzese A; Mangiacavalli S; Zamagni E; Califano C; Musso M; Conticello C; Cerchione C; Mele G; Di Renzo N; Offidani M; Tarantini G; Casaluci GM; Rago A; Ria R; Uccello G; Barilà G; Palumbo G; Pettine L; Vincelli ID; Brunori M; Accardi F; Amico V; Amendola A; Fontana R; Bongarzoni V; Rossini B; Cotzia E; Gozzetti A; Rizzi R; Sgherza N; Reddiconto G; Maroccia A; Franceschini L; Bertuglia G; Nappi D; Barbieri E; Gamberi B; Petrucci MT; Di Raimondo F; Neri A; Morabito F; Musto P; Gentile M
Hematol Oncol; 2024 Jul; 42(4):e3290. PubMed ID: 38818978
[TBL] [Abstract][Full Text] [Related]
58. Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials.
Zheng Y; Shen H; Xu L; Feng J; Tang H; Zhang N; Chen X; Gao G
J Immunol Res; 2018; 2018():7646913. PubMed ID: 30050957
[TBL] [Abstract][Full Text] [Related]
59. Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice.
Terpos E; Katodritou E; de la Rubia J; Hungria V; Hulin C; Roussou M; Delforge M; Bries G; Stoppa AM; Aagesen J; Sargin D; Belch A; Ahlberg L; Diels J; Olie RA; Robinson D; Spencer M; Potamianou A; van de Velde H; Dimopoulos MA
Eur J Haematol; 2018 Oct; 101(4):556-565. PubMed ID: 30027641
[TBL] [Abstract][Full Text] [Related]
60. Modified bortezomib, adriamycin and dexamethasone (PAD) regimen in advanced multiple myeloma.
Zhang Y; Liu H; Chen X; Bai Q; Liang R; Shi B; Liu L; Tian D; Liu M
Pathol Oncol Res; 2014 Oct; 20(4):987-95. PubMed ID: 24942506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
